InnoVec Biotherapeutics' AAV Gene Therapy IVB103 Granted IND Approval in China for nAMD Treatment

Oct 17, 2024 08:25 CST Updated 08:25

Innovecbio

Gene Editing Delivery Technology and Drug Developer

On October 15, 2024, Innovecbio's IVB103 Injection received clinical approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA); the product has already beenReceived FDA IND approval in July。

IVB103 Injection is a drug developed on the basis of Innovecbio's independently researched and developed novel vector for intravitreal administration to treat neovascular age-related macular degeneration (nAMD). Preclinical data show that IVB103 outperforms other advanced products in the same category currently under research internationally, demonstrating "best in class" potential.

About Innovecbio

InnoVec Biotherapeutics Inc. (Innovecbio) is a clinical-stage gene therapy company driven by vector innovation. The company is dedicated to developing gene therapy delivery tools suitable for human use, addressing the challenges of translating delivery tools from animals to humans. Its goal is to find gene delivery tools for all tissues and organs, enabling gene therapy to be widely applied to both rare and common diseases. InnoVec Biotherapeutics has highly efficient teams in technology development, pipeline research, process optimization, and clinical operations. It has established a leading technology development platform covering multiple disease areas such as ophthalmology, neurology, and muscular diseases. Several innovative products have entered the IIT and IND stages.

E.N.D

Previous article recommendations:

The World's First siRNA Chronic Disease Drug Participates in National Medical Insurance Negotiations for the First Time

Swei Bankrupt, Zhang Lei Returns to China, a New Cycle for Pharmaceutical Venture Capital Begins!

Beijing Releases "High-Quality Construction of Cell and Gene Therapy Industry Cluster Implementation Plan (2024-2026) (Draft for Comments)"

Hengrui Medicine Subsidiary’s AAV Dual-Gene Drug Approved for Clinical Trials in China

Ruijian Pharmaceuticals Completes Over 100 Million Yuan in Series B Financing

Akeso Biopharma Successfully Raises HKD 1.942 Billion

Former mRNA Vaccine Star Company Enters Bankruptcy Proceedings

Clinical Results of In Vivo CAR-T Therapy Published for the First Time

Total Investment of 128 Million Yuan: This Cell and Gene Therapy CDMO Platform in China Officially Unveiled

Global Leading Major Breakthrough! 20 Children with Refractory Lupus Erythematosus Successfully Discontinued All Hormones and Immunosuppressants After Receiving CAR-T Therapy at Children's Hospital of Zhejiang University

mRNA-LNP In Vivo Gene Editing Therapy Advances to Phase 3 Clinical Trials

Northland Shanghai Branch Opens, Fully Layouts the Commercialization of Gene Therapy Drug NL003

Guangdong Issues New Policy to Support the R&D of Innovative Biologics such as Gene Therapy and Cell Therapy, Focusing on Developing New Fields and Tracks like Gene Technology, Cell Therapy, and Synthetic Biology

New Drug for ALS Approved! Biogen's "Tofersen Injection" Launched in China

WuXi AppTec Responds to Rumors of Selling Cell and Gene Therapy Business, Citing Uncertainty

Nature Headline! Chinese Scholars Publish the World's First Universal CAR-T Therapy Achievement

InnoVec Biotherapeutics' iPS Cell-Derived Cell Therapy IND Accepted for Review

Covering an Area of Over 30,000 Square Feet, Legend Biotech Builds New Cell Therapy R&D Base

Fosun Pharma to Build China's Strongest, Most Comprehensive Cell Therapy Pipeline in Shanghai, Strengthening R&D of Innovative Oncology Drugs

NHFPC: Measures for the Administration of IIT Research in Medical and Health Institutions to Take Effect on October 1 (with Interpretation)

Ten Key Areas in China's Biopharmaceutical Industry to Watch in the Next Decade

Competitive Landscape of Gene Editing Therapy in China

Total investment of 500 million yuan, construction area of 88,000 square meters! Carson Cell Group · Yellow River International Life Science Industrial Park commences construction

New Strategy to Improve AAV Yield: Enhancing ER Protein Processing Gene Expression Can Increase AAV Production by 100%

SoundNote: The reference materials are sourced from the official company.This article is intended for knowledge sharing. All content is for reference only and does not constitute any advice.